title: Food and Drug Administration Procedures for New Drug and Device Approvals.
authors.affiliation: Ocular Inflammatory Disease Center, UCLA Stein Eye Institute and the Department of Ophthalmology, David Geffen School of Medicine at UCLA, Los Angeles, California. Electronic address: uveitis@jsei.ucla.edu.
authors.forename: Gary N
authors.initials: GN
authors.lastname: Holland
authors.affiliation: Division of Ophthalmic and Ear, Nose, and Throat Devices, Office of Device Evaluation, Center for Devices and Radiological Health, Food and Drug Administration, Silver Spring, Maryland.
authors.forename: Malvina B
authors.initials: MB
authors.lastname: Eydelman
authors.affiliation: Division of Ophthalmic and Ear, Nose, and Throat Devices, Office of Device Evaluation, Center for Devices and Radiological Health, Food and Drug Administration, Silver Spring, Maryland.
authors.forename: Brad
authors.initials: B
authors.lastname: Cunningham
authors.affiliation: Division of Transplant & Ophthalmology Products, Office of Antimicrobial Products, Office of New Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland.
authors.forename: Wiley A
authors.initials: WA
authors.lastname: Chambers
mesh_terms: D005128:Eye Diseases / Q000145:classification* / Q000175:diagnosis*; D005260:Female; D006801:Humans; D007908:Lens, Crystalline / Q000503:physiopathology*; D008297:Male; D041623:Tomography, Optical Coherence / Q000379:methods*; D014605:Uveitis / Q000150:complications*; D014821:Vitrectomy; D014822:Vitreous Body / Q000473:pathology*